Biotech Investing for Clinicians & Deal Professionals

How drugs, devices, and platforms are discovered, developed, evaluated, funded, and scaled

Translate clinical insight into venture-grade fundable biotech opportunities.

Including biomedical, therapeutic, diagnostic, and life-sciences investing contexts

(VIRTUAL: for the Scientist, Physician, MD, PhD, Analyst, Biomedical Entrepreneur, Investment & Financial Executive, Graduate)

Start Date Update: The course now begins Wednesday April 15, allowing additional clinicians and deal teams to join following the Spring Break holiday period.

(April 15, 2026 to June 17, 2026)

(Wednesdays - 6:30PM EST to 9:00PM EST)

‍Biotech Enterprise Investments: From Concept to Capital
Weekly Asynchronous + Optional Live Online | 10 Weeks* | Tuition: $2,495
Wednesday, April 15– Wednesday, June 17, 2026

Designed to fit around clinical and professional schedules.

About the Course

Many clinicians and scientists observe problems in disease treatment, workflow, or unmet need — but lack a structured pathway to translate those insights into venture-grade biotech opportunities.

This program provides that structure.

Biotech is one of the world’s most dynamic and capital-intensive sectors. Success requires more than scientific insight; it demands the ability to translate discovery into viable commercial and investment opportunities. Over 10 weeks and evenings interact virtually with colleagues to develop or analyze new biotech launches and relationships, explore monetization pathways.

This course bridges science, strategy, finance, and ethics to equip participants with the skills needed to discover, develop, commercializes, fund, and position biotechnology candidates and ventures. Through SEGP’s BLO team framework, participants work collaboratively to produce real, investment-ready concepts addressing unmet clinical, environmental, or industrial needs. The program is delivered over 10 weeks through asynchronous weekly modules, with optional live sessions, and is designed to fit around clinical and professional schedules. The course framework integrates applied commercialization methodology with research-driven disease contexts (or clinical observations) developed through original academic work and industry practice. Registration buttons are at the bottom of this page, including early-bird discounts.

What You’ll Learn 
 • Research diseases, devices, diagnostics of interest.

 • Develop clinical, development, and commercialization strategies
 • Convert complex research into investor-ready cases
 • Navigate regulatory, IP, and market-entry considerations
 • Build financial projections and capital strategies
 • Integrate bioethical principles into product development
 • Monetize venture concepts or present to a simulated or live investor panel

e sessions will be recorded but preliminary sessions may not be recorded.

Team-Based Venture Development
Participants form interdisciplinary teams to simulate the early development of new biotech ventures. Teams identify unmet clinical or market needs, assess scientific and commercial feasibility, and develop an investment-ready pitch deck, among others. Projects culminate in formal presentations focused on strategy, risk, and value creation, with structured feedback and, where appropriate, consideration for direct investment interest.

Who Should Enroll (Professional Orientation): This course is intended for clinicians, scientists, medical doctors, analysts, biotech entrepreneurs, and investment professionals seeking a practical understanding of biotech investment processes. Content emphasizes analytical frameworks, clinical risk assessment, and deal structures commonly encountered in life sciences investing.

Instructor
Daniel (E. St. Mark) Latty, PhD is an investor, operator, and educator with more than 25 years bridging life sciences, finance, and real assets. He has led and taught research-driven biotechnology business development programs at a leading research university, developed venture teams across therapeutic, diagnostic, environmental, agricultural, and industrial domains, and previously designed and taught a Venture Capital & Private Equity MBA course. His peer-reviewed articles appear in leading publications. He holds advanced degrees in biotechnology, finance, data science, and real estate development, and previously was a medical doctoral degree program candidate. He has attended Carnegie Mellon, Harvard, Johns Hopkins, NYU, and the University of Pittsburgh.

Apply for Spring 2026 Cohort.

Course Format

‍The course is virtual and includes investor pitch opportunities, bioethical analysis, and team-based venture / product creation. ‍

‍The course is both live and asynchronous for projects and recorded lectures.

Online sessions are on Wednesdays 6:30 PM EST to 9:00 PM EST. Sessions are recorded if missed, but live interaction is encouraged.

‍Course will be offered on a platform and uses certain tools allowing participants to work seamlessly in different time zones and locations, and presented in English.

‍Course participants gain access to instructor and experts outside of live class time.

The course structure, enrichment activities, and team dynamics may lead team members to develop vibrant network of life-long friends and business associates.

During or at the end of the course, it is a possibility that participants may analyze, launch, or grow new or existing biotech enterprises or develop new product-concepts. A followup Strategic Biotechnology Development & Investments course is being planned as a sequel to this course.

The course is structured to accommodate clinical schedules, deal workflows, and professional obligations.

*Note: An optional one week free prerequisite session is available for registered participants who need preliminary workup depending if you are from a science/technical or investments background. This may result in ~11 weeks with an additional one week of two free preliminary sessions for registered particpants that would take place between April 3, 2026 and April 14, 2026 between 7:00 PM EST and 9:00 PM EST. Regular course sessions will be recorded but preliminary sessions may not be recorded.